Youth Overdose & Use Reduction in Rural Systems (YOURS)
YOURS Study: Youth Overdose & Use Reduction in Rural Systems
The goal of this study is to conduct a clinical trial to understand effects of providing multilevel intervention to young people in the legal system. The multilevel intervention includes flexible care management using ACRA/ACC principles, family support, and overdose education. This study aims to test the implementation strategy, as well as the outcomes of the intervention with participants.
The first question the study will address is how successful was implementation. This will be measured by the number of youth receiving case management, family support, naloxone supplies, and overdose prevention curricula, and adoption by the participating county court systems.
The second question the study will address is whether the intervention impacted youth behavioral outcomes, such as overdose risk awareness, knowledge of how to use naloxone, and number of days per month using substances.
Researchers will compare youth who received the intervention to youth who received usual treatment to see if the intervention increases overdose risk awareness and knowledge, and decreases frequency of substance use.
Participants will receive the intervention (if assigned to) and complete study surveys. Participating counties will provide data on implementation, and site visits will also be performed to track each county's performance.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Youth involved in the legal system (YILS) have some of the highest rates of substance and opioid use disorders (SUD/OUD) nationally; but few have access to adequate resources to prevent serious sequelae. SUD prevention and overdose prevention interventions for YILS are critically important to delay escalation to synthetic opioids and prevent fatalities and other health, and legal consequences.
Washington State is facing an overdose crisis; between August 2022 and 2023, overdose deaths in this state increased by 40%, a steeper increase than any other state. Rural counties in this state report overdose rates that are as high or higher than urban ones. YILS, even those without OUD, are especially vulnerable to unintentional overdose; amongst YILS incarcerated in Washington State system completing a drug and alcohol assessment, 58% had experienced an overdose at some point in the past (unpublished data). Substance use resources in this and other states for rural YILS are critical and sparse.
Working with counties on a prevention strategy will further the goal of intervening with YILS who are, on average, earlier in the spectrum of legal and substance use involvement. Prior to this trial, the research team completed a codesign process with various stakeholders to design an intervention. Codesign invites people with lived experience to the design process with the goal of designing a more effective intervention. The codesign group consisted of youth and caregivers with lived experience with substance use or the juvenile court system, behavioral health providers, funding sector representatives, and juvenile county court administrators.Participating counties will be randomized into 6 clusters of the stepped wedge design. Control group participant data collection will begin for all counties at the same time. Clusters of counties will step into the implementation stage every 3-months. When counties move into the implementation stage, intervention group participant data collection will immediately begin.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Youth age 14-18
- Current juvenile court-involvement or receiving services from a participating county court (includes detention, diversion, truancy, at-risk youth, etc.)
- Received a REDCap link or QR code and study participation code from authorized county staff
Exclusion Criteria:
- Youth age 13 and under
- Youth who do not receive a study participation code from an authorized county contact
- Unable to participate due to significant mental health or developmental issue precluding meaningful participation in study procedures and/or intervention
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Versorgungsforschung
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Doppelt
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Intervention: YOURS Navigator Program
The intervention consists of a navigator stationed in each participating county or shared by neighboring counties. The navigator will deliver a flexible care management intervention, including direct services and referrals to court-involved youth in rural Washington counties. |
Care Navigator who will work with youth and families to address mental health, substance use, and other unmet needs, both through direct support services as well as referrals to adjunctive agencies. The flexible care management intervention may include goal setting, skill building, contingency management, motivational interviewing, overdose prevention and education, mental health and substance first aid, and basic needs support. The Navigator will work closely with the youth for 3-months, and as-needed up to 6-months.
Andere Namen:
|
|
Kein Eingriff: Usual Care
No Navigator intervention during the control time period. The juvenile court system may refer adolescents to their usual care pathways. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overdose Prevention Knowledge
Zeitfenster: 3- and 6-months
|
Youth knowledge on how to prevent and/or respond to an overdose. Assessed using the Opioid Overdose Knowledge Scale (OOKS). Scores range from 0-45 and a higher score is considered a better outcome. |
3- and 6-months
|
|
Presence of use past 30 days (Yes/No)
Zeitfenster: 3- and 6-months
|
Use of any overdose associated substance (opioids, benzodiazepines, alcohol, or stimulants) in the past 30 days; use of any substance in the past 30 days |
3- and 6-months
|
|
Number of days using alcohol and cannabis
Zeitfenster: 3- and 6-months
|
In the past 30 days, number of days youth used cannabis; in the past 30 days, number of days youth used alcohol. |
3- and 6-months
|
|
Number of youth receiving case management, mental health, or substance use prevention services
Zeitfenster: Through study completion, up to 30 months
|
Primary implementation outcome - county level |
Through study completion, up to 30 months
|
|
Number of naloxone kits distributed
Zeitfenster: Through study completion, up to 30 months
|
Primary implementation outcome - county level |
Through study completion, up to 30 months
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of days of using other individual non-alcohol/non-cannabis substances
Zeitfenster: 3- and 6- months
|
Measure taken from the HEAL Prevention Cooperative Common Core Measures |
3- and 6- months
|
|
Substance use refusal self-efficacy
Zeitfenster: 3- and 6-months
|
How confident youth are resisting substances. |
3- and 6-months
|
|
Percent of youth reporting receipt of naloxone
Zeitfenster: 3 months
|
Percent of youth receiving naloxone, a medication to reverse an opioid overdose. |
3 months
|
|
Number of youth receiving overdose prevention education
Zeitfenster: Through study completion, up to 30 months
|
Secondary implementation outcome - county level |
Through study completion, up to 30 months
|
|
Number of court staff receiving overdose prevention education
Zeitfenster: Through study completion, up to 30 months
|
Secondary implementation outcome - county level |
Through study completion, up to 30 months
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Presence of non-fatal overdose
Zeitfenster: 3- and 6-months
|
Exploratory outcome, investigator-developed |
3- and 6-months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 2026-007-SCH
- R61DA061846 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
De-identified data will be shared with investigators who propose a specific data analysis plan that is reviewed and approved by study PIs, unless prohibited by NIDA, IRB, or another regulatory body (e.g., DSMB).
IPD-Sharing-Zeitrahmen
IPD and supporting information will be available at the end of the study (March 2029) for up to 5 years (through February 2034).
IPD-Sharing-Zugriffskriterien
Investigators need to submit a brief description of how they will use the data to our team to access data and supporting information. Investigators will send a dataset once the project is approved.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .